NCT00663429View on ClinicalTrials.gov

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

Atiprimod

Oral, 14 days on / 14 days off; 30mg capsules

Trial Locations (2)

10029

Mount Sinai Medical Center, New York

72205

Hematology Oncology Services of Arkansas, Little Rock

Sponsors
All Listed Sponsors
lead

Callisto Pharmaceuticals

INDUSTRY